Identifying The Need
Many developed and in-pipeline drugs exhibit poor aqueous
solubility, poor bioavailability with associated challenges
of delayed onset of action, food effects and high inter-subject
variability. Hence, large doses of the active ingredient
have to be administered more frequently to achieve and
maintain desired therapeutic profiles.
The Rubicon Research Breakthrough
Rubicon Research's RubiEnTM
technology increases the bioavailability of drugs by
enhancing the solubility and dissolution rates in acidic
environment (pH < 3). An active ingredient is treated
with an excipient that increases its solubility and
dissolution rate significantly which enables the drug
product to achieve a pH-independent dissolution profile.
The novel technology, RubiEnTM,
increases the absorbable form of the active ingredient
in the GI tract and thereby improves its bioavailability.
The
System Performance
Intellectual
Property
The RubiEnTM technology is covered by pending
patent applications.
Key
Attributes of RubiEnTM
• Versatile with respect to the category of the
drug molecule
• Suitable with respect to drugs having different
doses
• Excipients employed are traditional and pharmacopoeial
• Conventional method of manufacture
Benefits
• Improved bioavailability and better utilisation
of the drug
• Rapid onset of action
• Reduction in dose
• Reduction in variability of bioavailability
• Reduced adverse reactions
• Better compliance
• Patient convenience
